# OnCo record checkpoint-inhibitor (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/checkpoint-inhibitor/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "checkpoint-inhibitor" ;
  schema:name "Immune checkpoint inhibitors"@en ;
  schema:description "Immune checkpoint inhibitors are antibodies against CTLA-4, PD-1 or PD-L1 that release the brakes on T cells so they attack the cancer. They are approved in more than 20 tumour types and produce lasting, sometimes curative responses that chemotherapy rarely does, but most patients do not respond and autoimmune side effects are the cost."@en ;
  schema:url <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Checkpoint_inhibitor> ;
  owl:sameAs <http://www.wikidata.org/entity/Q39086981> ;
  schema:citation <https://en.wikipedia.org/wiki/Checkpoint_inhibitor>, <https://www.nice.org.uk/guidance/ng122/chapter/Management>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/pembrolizumab>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/durvalumab>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/atezolizumab>, <https://doi.org/10.1182/blood-2010-05-282780>, <https://doi.org/10.1200/JCO.2016.66.4482>, <https://doi.org/10.1056/NEJMoa1411087>, <https://doi.org/10.1200/JCO.2017.77.3994> ;
  onco:status "standard-of-care" ;
  onco:related <https://onco.cc/technologies/tigit-blockade/>, <https://onco.cc/technologies/tim3-blockade/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/tigit/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/compass-therapeutics/>, <https://onco.cc/companies/eris-biotech/>, <https://onco.cc/companies/onc-ai/>, <https://onco.cc/companies/ose-immunotherapeutics/>, <https://onco.cc/companies/persephone-biosciences/>, <https://onco.cc/companies/xilio-therapeutics/>, <https://onco.cc/companies/mabquest/>, <https://onco.cc/companies/ascendo-biotechnology/>, <https://onco.cc/companies/bright-peak-therapeutics/>, <https://onco.cc/companies/pheast-therapeutics/>, <https://onco.cc/companies/zumutor-biologics/>, <https://onco.cc/companies/biond-biologics/>, <https://onco.cc/companies/solstice-oncology/> ;
  onco:terms <https://onco.cc/terms/cps/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/rationale-302/> ;
  onco:people <https://onco.cc/people/lieping-chen/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/>, <https://onco.cc/key-papers/paper-chen-mellman-cancer-immunity-cycle-immunity-2013/>, <https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/>, <https://onco.cc/key-papers/paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017/>, <https://onco.cc/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/>, <https://onco.cc/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/>, <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/>, <https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/>, <https://onco.cc/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/>, <https://onco.cc/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/>, <https://onco.cc/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/> ;
  onco:journals <https://onco.cc/journals/cancer-immunology-immunotherapy/>, <https://onco.cc/journals/journal-of-immunotherapy/>, <https://onco.cc/journals/oncoimmunology/> ;
  onco:dependsOn <https://onco.cc/technologies/monoclonal-antibody/> .